Evidence map›Paper›PMID 30151320›Full record

ReviewMycology2015

Cordyceps industry in China.

Caihong Dong, Suping Guo, Wenfeng Wang, Xingzhong Liu

Open access · goldAbstract readReview
In one paragraph

Review in Mycology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 116 citations in OpenAlex.

  1. Article
  2. Evolutionary insights intoIMA fungus · 2026
    Article
  3. Article
  4. The Conservation Crisis ofJournal of fungi (Basel, Switzerland) · 2025
    Review
  5. Article
  6. Telomere-to-Telomere Assembly of theJournal of fungi (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Polysaccharides fromMolecules (Basel, Switzerland) · 2023
    Article
  18. Review
  19. The Health and Clinical Benefits of Medicinal Fungi.Advances in biochemical engineering/biotechnology · 2023
    Article
  20. Optimization ofHeliyon · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Caihong DongState Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, No 3 Park 1, Beichen West Road, Chaoyang District, Beijing100101, China.
Suping GuoBioengineering Laboratory, Shanxi Research Institute for Medicine and Life Science, Taiyuan030006, China.
Wenfeng WangResearch and Development Department, Jiangsu Shenhua Pharmaceutical Co., Ltd., Huaian211600, China.
Xingzhong LiuState Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, No 3 Park 1, Beichen West Road, Chaoyang District, Beijing100101, China.
China Shenhua Energy (China) · CNChinese Academy of Sciences · CNInstitute of Microbiology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cordyceps, as a general term, describes a group of ascomycetous fungi growing on arthropods and other related fungi. Some cordyceps have been used in traditional Chinese medicine for centuries and cordyceps-derived products are currently a big industry in China. A number of medicinal and health products have been developed and extensively commercialized from natural Chinese cordyceps, its anamorphic fungus (

Indexed as

Chinese cordycepsChinese cordyceps–associated fungicordycepscordyceps fungusindustry

Identifiers

PMID30151320
PMCPMC6106062
OpenAlexW2150745171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.